All News

Found 5,918 articles

• Cyclacel Pharmaceuticals, Inc. to Host Conference Call to Review Sapacitabine Phase I Hematology Data on June 12, 2007

  6/8/2007

• Pharmion Corporation Clinical Data Presented on Pilot Pharmacokinetic Study of Oral Azacitidine

  6/4/2007

• Pharmion Corporation Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors

  6/4/2007

• Pharmion Corporation and MethylGene Report Preliminary Data for MGCD0103 at the 43rd American Society of Clinical Oncology Annual Meeting

  6/4/2007

• Cyclacel Pharmaceuticals, Inc. Reports Phase I Sapacitabine Data in Patients with Advanced Leukemias and Myelodysplastic Syndromes at 2007 American Society of Clinical Oncology Annual Meeting

  6/4/2007

• Pharmion Corporation to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology Meeting

  6/1/2007

• IDM Pharma, Inc. Announces UVIDEM(R) and EP-2101 Data Presentations at 2007 American Society of Clinical Oncology Annual Meeting

  5/31/2007

• Callisto Pharmaceuticals Opens Fourth Site for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients

  5/24/2007

• Tempo Pharmaceuticals Closes $12.1 Million in Series A Funding

  5/23/2007

• Endocare, Inc. First Randomized Head-to-Head Study Shows Cryoablation at Least as Effective as External Beam Radiation for Treating Localized Prostate Cancer

  5/23/2007

• Bristol-Myers Squibb Company Joins Oslo Cancer Cluster

  5/4/2007

• VioQuest Pharmaceuticals, Inc. Announces Phase I/IIa Trial and Enrollment Updates for Akt Inhibitor VQD-002

  4/27/2007

• Pharmion Corporation Oral Azacitidine Advances to Multi-Center, Multi-Cycle, Dose Escalation Study

  4/23/2007

• Bridgetech Sponsors Major Oncology Conference in China - The 2007 Asia-Pacific Conference of Tumor Biology and Medicine

  4/17/2007

• Novartis Corporation Suspends US Marketing and Sales of Zelnorm(R) in Response to Request from FDA

  3/30/2007

• VioQuest Pharmaceuticals, Inc. Reports Year End 2006 Financial Results

  3/30/2007

• Napo Pharmaceuticals, Inc. Obtains IRB Approval for Phase 3 Clinical Trial Protocol for Crofelemer In HIV/AIDS Diarrhea Assessment

  3/14/2007

• Callisto Pharmaceuticals Announces Patient Dosing in L-Annamycin Phase I Clinical Trial in Pediatric Relapsed or Refractory Acute Leukemia

  3/8/2007

• Prostate Cancer Foundation Awards $6.1 Million to Record Number of Competitive Award Recipients

  3/5/2007

• Callisto Pharmaceuticals Opens L-Annamycin Phase I Clinical Trial In Pediatric Relapsed Or Refractory Acute Leukemia

  2/22/2007